Improved Drug Delivery System for Cancer Treatment by D-Glucose Conjugation with Eugenol From Natural Product

Mas    Amira Idayu Abdul    Razak; Haslinda    Abdul    Hamid; Raja    Nor Izawati Raja    Othman; Shaik    Alaudeen Mohd    Moktar; Azizi       Miskon

doi:10.2174/1567201817666200917123639

Abstract

Introduction: Bioconjugations are swiftly progressing and are being applied to solve several limitations of conventional Drug Delivery Systems (DDS) such as lack of water solubility, non-specific, and poor bioavailability. The main goals of DDS are to achieve greater drug effectiveness and minimize toxicity to the healthy tissues.

Objectives and Methods: In this study, D-glucose was conjugated with eugenol to target the cancer cells. To identify the implication of the anticancer effect, osteosarcoma (K7M2) cells were cultured and the anti-proliferative effect was performed using MTT [3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyl tetrazolium bromide assay] test in order to evaluate the viability and toxicity on cells with various concentrations of eugenol and D-glucose-eugenol conjugate in 24-hour incubation.

Results: It was found that, the successful confirmation of the conjugation between D-glucose and eugenol was obtained by 1H NMR spectroscopy. MTT assay showed inhibitory concentration (IC50 value) of D-glucose-eugenol was at 96.2 μg/ml and the decreased of osteosarcoma cell survival was 48%.

Conclucion: These findings strongly indicate that K7M2 cells would be affected by toxicity of Dglucose- eugenol. Therefore, the present study suggests that D-glucose-eugenol has high potential to act as an anti-proliferative agent who may promise a new modality or approach as the drug delivery treatment for cancer or chemotherapeutic agent.

Keywords: Conjugation, D-glucose, eugenol, Drug Delivery Systems (DDS), cancer treatment, osteosarcoma (K7M2).

« Previous Next »

Graphical Abstract

[1] 
American cancer society. Cancer facts & figures 2016. Cancer Facts Fig.,  2016, 2016, 1-9.
[2] 
Wild, C.P. The global cancer burden: necessity is the mother of prevention. Nat. Rev. Cancer,  2019, 19(3), 123-124.
[http://dx.doi.org/10.1038/s41568-019-0110-3] [PMID:  30683893] 
[3] 
Debele, T.A.; Mekuria, S.L.; Tsai, H. Polysaccharide based nanogels in the drug delivery system: Application as the carrier of pharmaceutical agents. Mater. Sci. Eng. C Mater. Biol. Appl.,  2016, 68, 964-981.
[4] 
Granchi, C.; Fancelli, D.; Minutolo, F. An update on therapeutic opportunities offered by cancer glycolytic metabolism. Bioorg. Med. Chem. Lett.,  2014, 24(21), 4915-4925.
[http://dx.doi.org/10.1016/j.bmcl.2014.09.041] [PMID:  25288186] 
[5] 
Gomis, R.R. Survival skills ensure that cancer spreads. Nature,  2019, 573(7774), 353-354.
[http://dx.doi.org/10.1038/d41586-019-02570-z] [PMID:  31530905] 
[6] 
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell,  2011, 144(5), 646-674.
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID:  21376230] 
[7] 
Vijaya, S.; Sudhakar, Y.; Venkateswarlu, B. Current review on organophosphorus poisoning. Arch. Appl. Sci. Res.,  2010, 2(4), 199-215.
[8] 
Mortezaee, K. Modulation of apoptosis by melatonin for improving cancer treatment efficiency : an updated review. Life Sci.,  2019, 228, 228-241.
[9] 
Reddy, P.D.; Swarnalatha, D. Recent advances in novel drug delivery systems. J. Materials,  2010, 2(3), 2025-2027.
[10] 
Miskon, A.; Ibrahim, N.; Mohd Tawil, S.N. A model of Defence mechanical Drug delivery system (DmechD) and the drug release efficacy IECBES 2014.Conf. Proc. - 2014 IEEE Conf. Biomed. Eng. Sci. “Miri, Where Eng. Med. Biol. Humanit. Meet,  2015, pp. 22-26.
[11] 
Devi, V.K.; Jain, N.; Valli, K.S. Importance of novel drug delivery systems in herbal medicines. Pharmacogn. Rev.,  2010, 4(7), 27-31.
[http://dx.doi.org/10.4103/0973-7847.65322] [PMID:  22228938] 
[12] 
Saini, R.K.; Chouhan, R.; Bagri, L.P.; Bajpai, A.K. Strategies of targeting tumors and cancers. J. Cancer Res. Updates,  2012, 1(1), 129-152.
[13] 
Anselmo, A.C.; Mitragotri, S. An overview of clinical and commercial impact of drug delivery systems. J. Control. Release,  2014, 190, 15-28.
[http://dx.doi.org/10.1016/j.jconrel.2014.03.053] [PMID:  24747160] 
[14] 
Gothoskar, A.V.; Joshi, A.M. Drug delivery systems: an updated review. Int. J. Pharm. Investig.,  2012, 2(1), 2-11.
[15] 
Ricart, A.D. Drug-delivery systems in cancer therapy. Signal Transduct. Target. Therapy.,  2018, 3, 7.
[16] 
Hossen, S.; Hossain, M.K.; Basher, M.K.; Mia, M.N.H.; Rahman, M.T.; Uddin, M.J. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review. J. Adv. Res.,  2018, 15, 1-18.
[http://dx.doi.org/10.1016/j.jare.2018.06.005] [PMID:  30581608] 
[17] 
Faiz Norrrahim, M.N. Recent developments on oximes to improve the blood brain barrier penetration for the treatment of organophosphorus poisoning: a review. RSC Adv.,  2020, 10(8), 4465-4489.
[http://dx.doi.org/10.1039/C9RA08599H] 
[18] 
Shahriari, M.; Zahiri, M.; Abnous, K.; Taghdisi, S.M.; Ramezani, M.; Alibolandi, M. Enzyme responsive drug delivery systems in cancer treatment. J. Control. Release,  2019, 308, 172-189.
[http://dx.doi.org/10.1016/j.jconrel.2019.07.004] [PMID:  31295542] 
[19] 
Calvo, B.; Pulido, E.G. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int. J. Endocrinol.,  2010, Article ID 205357.
[20] 
Pastuch-Gawołek, G.; Malarz, K.; Mrozek-Wilczkiewicz, A.; Musioł, M.; Serda, M.; Czaplinska, B.; Musiol, R. Small molecule glycoconjugates with anticancer activity. Eur. J. Med. Chem.,  2016, 112, 130-144.
[http://dx.doi.org/10.1016/j.ejmech.2016.01.061] [PMID:  26890119] 
[21] 
Ferreira, L.M.R. Cancer metabolism: the Warburg effect today. Exp. Mol. Pathol.,  2010, 89(3), 372-380.
[http://dx.doi.org/10.1016/j.yexmp.2010.08.006] [PMID:  20804748] 
[22] 
Tateishi, U.; Miyake, M.; Nagaoka, T.; Terauchi, T.; Kubota, K.; Kinoshita, T.; Daisaki, H.; Macapinlac, H.A. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. Radiology,  2012, 263(1), 53-63.
[http://dx.doi.org/10.1148/radiol.12111177] [PMID:  22438441] 
[23] 
Currie, C.J.; Poole, C.D.; Gale, E.A.M. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia,  2009, 52(9), 1766-1777.
[24] 
Macheda, M.L.; Rogers, S.; Best, J.D. Molecular And Cellular Regulation Of Glucose Transporter (GLUT) proteins in cancer. J. Cell. Physiol.,  2005, 202(3), 654-662.
[http://dx.doi.org/10.1002/jcp.20166] [PMID:  15389572] 
[25] 
Krzeslak, A.; Wojcik-Krowiranda, K.; Forma, E.; Jozwiak, P.; Romanowicz, H.; Bienkiewicz, A.; Brys, M. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol. Oncol. Res.,  2012, 18(3), 721-728.
[http://dx.doi.org/10.1007/s12253-012-9500-5] [PMID:  22270867] 
[26] 
Li, L.; Kang, L.; Zhao, W.; Feng, Y.; Liu, W.; Wang, T.; Mai, H.; Huang, J.; Chen, S.; Liang, Y.; Han, J.; Xu, X.; Ye, Q. miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect. Cancer Lett.,  2017, 400, 89-98.
[http://dx.doi.org/10.1016/j.canlet.2017.04.034] [PMID:  28461244] 
[27] 
Sztandera, K.; Dzia, P.; Marcinkowska, M.; Sta, M. Sugar modification enhances cytotoxic activity of PAMAM-doxorubicin conjugate in glucose-deprived MCF-7 cells – possible role of GLUT1 transporter. Pharm. Res.,  2019, 36(10), 140.
[28] 
Seyfried, T.N.; Huysentruyt, L.C. On the origin of cancer metastasis. Crit. Rev. Oncog.,  2013, 18(1-2), 43-73.
[http://dx.doi.org/10.1615/CritRevOncog.v18.i1-2.40] [PMID:  23237552] 
[29] 
Calvaresi, E.C.; Hergenrother, P.J. Glucose conjugation for the specific targeting and treatment of cancer. Chem. Sci. (Camb.),  2013, 4(6), 2319-2333.
[http://dx.doi.org/10.1039/c3sc22205e] [PMID:  24077675] 
[30] 
Amann, T.; Maegdefrau, U.; Hartmann, A.; Agaimy, A.; Marienhagen, J.; Weiss, T.S.; Stoeltzing, O.; Warnecke, C.; Schölmerich, J.; Oefner, P.J.; Kreutz, M.; Bosserhoff, A.K.; Hellerbrand, C. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am. J. Pathol.,  2009, 174(4), 1544-1552.
[http://dx.doi.org/10.2353/ajpath.2009.080596] [PMID:  19286567] 
[31] 
Patra, M.; Johnstone, T.C.; Suntharalingam, K.; Lippard, S.J. Medicinal inorganic chemistry A potent glucose – platinum conjugate exploits glucose transporters and preferentially accumulates in cancer cells. Angew. Chem. Int. Ed. Engl.,  2016, 55(7), pp. 2550-2554.
[32] 
Tanaka, M.; Kataoka, H.; Yano, S.; Ohi, H.; Kawamoto, K.; Shibahara, T.; Mizoshita, T.; Mori, Y.; Tanida, S.; Kamiya, T.; Joh, T. Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells. BMC Cancer,  2013, 13(1), 237.
[http://dx.doi.org/10.1186/1471-2407-13-237] [PMID:  23672493] 
[33] 
Li, H.; Gao, X.; Liu, R.; Wang, Y.; Zhang, M.; Fu, Z.; Mi, Y.; Wang, Y.; Yao, Z.; Gao, Q. A potent glucose – platinum conjugate exploits glucose transporters and preferentially accumulates in cancer cells. Angewandte,  2015, 2550-2554.
[34] 
Granchi, C.; Fortunato, S.; Minutolo, F. Anticancer agents interacting with membrane glucose transporters. MedChemComm,  2016, 7(9), 1716-1729.
[http://dx.doi.org/10.1039/C6MD00287K] [PMID:  28042452] 
[35] 
Pourcel, L.; Routaboul, J.M.; Cheynier, V.; Lepiniec, L.; Debeaujon, I. Flavonoid oxidation in plants: from biochemical properties to physiological functions. Trends Plant Sci.,  2007, 12(1), 29-36.
[http://dx.doi.org/10.1016/j.tplants.2006.11.006] [PMID:  17161643] 
[36] 
Kashyap, D.; Tuli, H.S.; Yerer, M.B. Natural product-based nanoformulations for cancer therapy: opportunities and challenges. Seminars. Cancer Biol., 2019. Epub ahead of print
[37] 
Ghosh, R.; Nadiminty, N.; Fitzpatrick, J.E.; Alworth, W.L.; Slaga, T.J.; Kumar, A.P. Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity. J. Biol. Chem.,  2005, 280(7), 5812-5819.
[http://dx.doi.org/10.1074/jbc.M411429200] [PMID:  15574415] 
[38] 
Choudhury, P.; Barua, A.; Roy, A.; Pattanayak, R.; Bhattacharyya, M.; Saha, P. 
            Eugenol restricts cancer stem cell population by degradation of β-catenin 
            
              via
            
             N-terminal Ser37 phosphorylation-an i
            
              n vivo 
            
            and
            
               in vitro
            
             experimental evaluation.
           Chem. Biol. Interact.,  2020, 316, 108938.
[http://dx.doi.org/10.1016/j.cbi.2020.108938] [PMID:  31926151] 
[39] 
Hemaiswarya, S.; Doble, M. Synergistic interaction of phenylpropanoids with antibiotics against bacteria. J. Med. Microbiol.,  2010, 59(Pt 12), 1469-1476.
[http://dx.doi.org/10.1099/jmm.0.022426-0] [PMID:  20724513] 
[40] 
Pramod, K.; Ansari, S.H.; Ali, J. Eugenol: a natural compound with versatile pharmacological actions. Nat. Prod. Commun.,  2010, 5(12), 1999-2006.
[http://dx.doi.org/10.1177/1934578X1000501236] [PMID:  21299140] 
[41] 
Lanzillotto, M.; Konnert, L.; Lamaty, F.; Martinez, J.; Colacino, E. Mechanochemical 1,1′-carbonyldiimidazole-mediated synthesis of carbamates. ACS Sustain. Chem.& Eng.,  2015, 3(11), 2882-2889.
[http://dx.doi.org/10.1021/acssuschemeng.5b00819] 
[42] 
Thorpe, C.; Epple, S.; Woods, B.; El-Sagheer, A.H.; Brown, T. Synthesis and biophysical properties of carbamate-Locked Nucleic Acid (LNA) oligonucleotides with potential antisense applications. Org. Biomol. Chem.,  2019, 17(21), 5341-5348.
[http://dx.doi.org/10.1039/C9OB00691E] [PMID:  31099373] 
[43] 
Montalbetti, C.A.G.N.; Falque, V. Amide bond formation and peptide coupling. Tetrahedron,  2005, 61(46), 10827-10852.
[http://dx.doi.org/10.1016/j.tet.2005.08.031] 
[44] 
Woodman, E.K.; Chaffey, J.G.K.; Hopes, P.A.; Hose, D.R.J.; Gilday, J.P. N,N′-carbonyldiimidazole-mediated amide coupling : significant rate enhancement achieved by acid catalysis with imidazole • HCl. Org. Process Res. Dev.,  2009, 6, 106-113.
[45] 
Onche, E.U.; Tukura, B.W.; Bako, S.S. Nuclear Magnetic Resonance (NMR) analysis of D - (+) - Glucose: a guide to spectrometric structural elucidation of sugars. IOSR J. Appl. Chem.,  2013, 6(1), 45-51.
[http://dx.doi.org/10.9790/5736-0614551] 
[46] 
Hu, P.; Ben-David, Y.; Milstein, D. Rechargeable hydrogen storage system based on the dehydrogenative coupling of ethylenediamine with ethanol. Angew. Chem. Int. Ed. Engl.,  2016, 55(3), 1061-1064.
[http://dx.doi.org/10.1002/anie.201505704] [PMID:  26211515] 
[47] 
Cary, R. 1,2-diaminoethane (ethylenediamine). World Health Org.,  1999, 27-28.
[48] 
Katritzky, A.R.; Monbaliu, J.C.M. The chemistry of benzotriazole derivatives: a tribute to Alan Roy Katritzky. Topics Heterocyclic Chem.,  2016, 43(43), 300.
[49] 
Ghosh, A.K.; Brindisi, M. Organic carbamates in drug design and medicinal chemistry. J. Med. Chem.,  2015, 58(7), 2895-2940.
[http://dx.doi.org/10.1021/jm501371s] [PMID:  25565044] 
[50] 
Reich, H.J. 5.2 Chemical shift; structure determination using spectroscopy. Methods,  2014, pp. 1-23.
[51] 
Gurst, J.E. NMR and the structure of D-glucose. Textb. Forum,  1991, 68(12), 1003-1004.
[http://dx.doi.org/10.1021/ed068p1003] 
[52] 
Ikeda, R.; Uyama, H.; Kobayashi, S. Novel synthetic pathway to a poly(phenylene oxide). laccase-catalyzed oxidative polymerization of syringic acid, no. Scheme,  1996, 1, 3053-3054.
[http://dx.doi.org/10.1021/ma951810b] 
[53] 
Meng, S.; Cao, J.; Feng, Q.; Peng, J.; Hu, Y. Roles of chlorogenic acid on regulating glucose and lipids metabolism: a review. Evid. Based Complement. Alternat. Med.,  2013, 2013, 22.
[54] 
Chen, L.; Teng, H.; Cao, H. 
            Chlorogenic acid and caffeic acid from 
            
              Sonchus oleraceus
            
             Linn synergistically attenuate insulin resistance and modulate glucose uptake in HepG2 cells.
           Food Chem. Toxicol.,  2019, 127, 182-187.
[http://dx.doi.org/10.1016/j.fct.2019.03.038] [PMID:  30914352] 
[55] 
Bagno, A.; Rastrelli, F.; Saielli, G. Prediction of the 1 H and 13 C NMR spectra of r - D -glucose in water by DFT methods and MD simulations. The J. Phys. Chem. A,  2007, pp. 7373-7381.
[56] 
Vidhya, N.; Devaraj, S.N. Induction of apoptosis by eugenol in human breast cancer cells. Indian J. Exp. Biol.,  2011, 49, 871-878.
[57] 
Baharara, J.; Ramezani, T.; Mousavi, M.; Kouhestanian, K. Eugenol suppressed metastasis of breast carcinoma cells and migration by regulation of MMP-9 & paxilin gene expression. Sch. J. Agric. Vet. Sci.,  2015, 2(2B), 125-130.
[58] 
Fisher, R.A. The use of multiple measurements in taxonomic problems. Annals Eugenics,  1954, 1(1), 1-8.
[59] 
Rothstein, E.L.; Hartzell, R.W., Jr; Manson, L.A.; Kritchevsky, D. Effects of D2O on cellular components of mammalian cells grown in tissue culture. Ann. NY. Acad. Sci.,  1960, 84(16), 721-726.
[http://dx.doi.org/10.1111/j.1749-6632.1960.tb39103.x] [PMID:  13743911] 
[60] 
Takeda, H.; Nio, Y.; Omori, H.; Uegaki, K.; Hirahara, N.; Sasaki, S.; Tamura, K.; Ohtani, H. Mechanisms of cytotoxic effects of heavy water (deuterium oxide: D2O) on cancer cells. Anticancer Drugs,  1998, 9(8), 715-725.
[http://dx.doi.org/10.1097/00001813-199809000-00007] [PMID:  9823430] 
[61] 
Patra, M.; Awuah, S.G.; Lippard, S.J. 
            Chemical approach to positional isomers of glucose-platinum conjugates reveals specific cancer targeting through glucose-transporter-mediated uptake 
            
              in vitro 
            
            and
            
               in vivo
            
            .
           J. Am. Chem. Soc.,  2016, 138(38), 12541-12551.
[http://dx.doi.org/10.1021/jacs.6b06937] [PMID:  27570149] 
[62] 
Sanae, F.; Kamiyama, O.; Ikeda-Obatake, K.; Higashi, Y.; Asano, N.; Adachi, I.; Kato, A. Effects of eugenol-reduced clove extract on glycogen phosphorylase b and the development of diabetes in db/db mice. Food Funct.,  2014, 5(2), 214-219.
[http://dx.doi.org/10.1039/C3FO60514K] [PMID:  24336787] 
[63] 
Singh, R.; Barden, A.; Mori, T.; Beilin, L. Advanced glycation end-products: a review. Diabetologia,  2001, 44(2), 129-146.
[http://dx.doi.org/10.1007/s001250051591] [PMID:  11270668] 
[64] 
Alphey, M.S.; Pirrie, L.; Torrie, L.S.; Boulkeroua, W.A.; Gardiner, M.; Sarkar, A.; Maringer, M.; Oehlmann, W.; Brenk, R.; Scherman, M.S.; McNeil, M.; Rejzek, M.; Field, R.A.; Singh, M.; Gray, D.; Westwood, N.J.; Naismith, J.H. 
            Allosteric competitive inhibitors of the glucose-1-phosphate thymidylyltransferase (RmlA) from 
            
              Pseudomonas aeruginosa
            
            .
           ACS Chem. Biol.,  2013, 8(2), 387-396.
[http://dx.doi.org/10.1021/cb300426u] [PMID:  23138692] 
[65] 
Jaganathan, S.K.; Supriyanto, E. Antiproliferative and molecular mechanism of eugenol-induced apoptosis in cancer cells. Molecules,  2012, 17(6), 6290-6304.

Rights & Permissions Print Cite

Article Metrics

22

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1567201817666200917123639	Print ISSN 1567-2018
Publisher Name Bentham Science Publisher	Online ISSN 1875-5704

Current Drug Delivery

Improved Drug Delivery System for Cancer Treatment by D-Glucose Conjugation with Eugenol From Natural Product

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Related Articles

Abstract